While the GeneSight Test is intended to provide helpful information to health care providers prescribing psychotropic medications, some of the genes evaluated on the GeneSight Test play a role in the metabolism or response to a broader range of medications. For certain non-psychiatric medications, the GeneSight Test results may provide valuable insights that can be helpful to prescribers. The GeneSight Table of Additional Medications shown below includes non-psychiatric medications where Clinical Pharmacogenetics Implementation Consortium (CPIC®) Guidelines (Level A or B) or the Food and Drug Administration (FDA) Table of Pharmacogenetic Associations (Sections 1 or 2) provide potentially actionable information based on the genes evaluated by GeneSight.
If your patient’s results indicate that they have a non-normal phenotype for a gene included on the GeneSight Table of Additional Medications, it may be helpful to review the relevant CPIC Guideline or FDA Table to help inform medication management. However, it is important to note that the information provided is mostly based on single gene-drug interactions, and there may be other genes involved in the metabolism or mechanism of action of these medications.

How do I Use CPIC Guidelines and the FDA Table for Medications not on the GeneSight Test?

  1. Use the GeneSight Table of Additional Medications to identify whether a medication has CPIC or FDA Guidance available, then assess if the patient has a non-normal phenotype for the gene associated with that medication.
  2. Visit the CPIC Guidelines1 or FDA Table of Pharmacogenetic Associations2 webpage and find the relevant information.
  3. Consider the CPIC or FDA Guidance alongside other clinical factors and resources such as clinical practice guidelines.

EXAMPLE: The medication clopidogrel is being considered for a CYP2C19 poor metabolizer.
Use the Medication Category (Cardiovascular) on the GeneSight Table of Additional Medications to locate the Medication (clopidogrel), Gene (CYP2C19), and CPIC or FDA Guidance links available. In this example, the patient’s pharmacogenomic test results indicate a non-normal phenotype for CYP2C19 (poor metabolizer).

ClinPGx Summary: The CPIC Dosing Guideline for clopidogrel recommends an alternative antiplatelet therapy for CYP2C19 poor or intermediate metabolizers (cardiovascular indications: prasugrel or ticagrelor if no contraindication; neurovascular indications: alternative P2Y12 inhibitor if clinically indicated and no contraindication.)

FDA Table of Pharmacogenetic Associations for CYP2C19 and Clopidogrel:

Drug Gene Affected subgroups+ Description of Gene-Drug Interaction
Clopidogrel CYP2C19 intermediate or poor metabolizers Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.

GeneSight Table of Additional Medications

Medications included on this table are approved by the FDA and have CPIC Level A/B or FDA Table Section 1/2 guidance for a Gene on the GeneSight Test.

Medication Category* Medication Name Gene(s) CPIC or FDA Guidance
Anti-Infectives efavirenz
voriconazole
CYP2B6
CYP2C19
CPIC Guideline | FDA Table
CPIC Guideline | FDA Table
Antiemetic dronabinol
meclizine
metoclopramide
ondansetron
CYP2C9
CYP2D6
CYP2D6
CYP2D6
FDA Table
FDA Table
FDA Table
CPIC Guideline
Antineoplastic belzutifan
erdafitinib
gefitinib
tamoxifen
CYP2C19
CYP2C9
CYP2D6
CYP2D6
FDA Table
FDA Table
FDA Table
CPIC Guideline
Antiseizure brivaracetam
clobazam
phenytoin/fosphenytoin
CYP2C19
CYP2C19
CYP2C9, HLA-B*15:02
FDA Table
FDA Table
CPIC Guideline | FDA Table
Cardiovascular carvedilol
clopidogrel
fluvastatin
mavacamten
metoprolol
propafenone
warfarin
CYP2D6
CYP2C19
CYP2C9
CYP2C19
CYP2D6
CYP2D6
CYP2C9
FDA Table
CPIC Guideline | FDA Table
CPIC Guideline
FDA Table
CPIC Guideline
FDA Table
CPIC Guideline | FDA Table
Dermatology abrocitinib CYP2C19 FDA Table
Female Sexual Dysfunction flibanserin CYP2C19 FDA Table
Metabolic Disorder eliglustat
nateglinide
CYP2D6
CYP2C9
FDA Table
FDA Table
Movement Disorder tetrabenazine CYP2D6 FDA Table
Muscarinic Receptor Agonist cevimeline CYP2D6 FDA Table
Narcolepsy pitolisant CYP2D6 FDA Table
Neuroimmune siponimod CYP2C9 FDA Table
Neuroleptic pimozide CYP2D6 FDA Table
NSAIDs (non-steroidal anti-inflammatory drugs) celecoxib
flurbiprofen
ibuprofen
meloxicam
piroxicam
CYP2C9
CYP2C9
CYP2C9
CYP2C9
CYP2C9
CPIC Guideline | FDA Table
CPIC Guideline | FDA Table
CPIC Guideline
CPIC Guideline | FDA Table
CPIC Guideline | FDA Table
Opioid Analgesics codeine
hydrocodone
oliceridine
tramadol
CYP2D6
CYP2D6
CYP2D6
CYP2D6
CPIC Guideline | FDA Table
CPIC Guideline
FDA Table
CPIC Guideline | FDA Table
Opioid Withdrawal lofexidine CYP2D6 FDA Table
Overactive Bladder tolterodine CYP2D6 FDA Table
PPIs (proton pump inhibitors) lansoprazole
omeprazole
pantoprazole
dexlansoprazole
CYP2C19
CYP2C19
CYP2C19
CYP2C19
CPIC Guideline
CPIC Guideline
CPIC Guideline | FDA Table
CPIC Guideline

* The medications listed are grouped into broader categories based on their FDA‑approved indications and other therapeutic classification information. While many of these medications have multiple uses and may belong to more specific pharmacologic subclasses, they have been consolidated into broader categories for clarity and ease of reference. This organizational approach is intended solely to enhance usability and does not replace the detailed classifications provided in individual prescribing information.

Content provided from CPIC Guidelines and the FDA Table of Pharmacogenetic Associations are subject to updates and modifications. Users should refer to https://www.clinpgx.org/cpic or https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations to confirm they are accessing the most current content. Evaluation of PGx data may lead to different interpretations by expert PGx groups, evidence grading bodies, or PGx companies. GeneSight genotype to phenotype conversion may not be consistent with CPIC genotype to phenotype conversion in all cases. The pharmacogenomic insights described in this white paper are derived solely from established genotype–phenotype relationships. These analyses do not account for phenoconversion or variability in drug response arising from drug–drug interactions, age-related changes, disease states, organ function, environmental influences, or other clinical factors. As such, the information contained herein should be interpreted within the context of a comprehensive medical assessment.

Have More Questions? We’re Here to Help
If you have a pharmacogenomics question about a medication listed below, our GeneSight Medical Information team is available to assist you. Please reach out to us by emailing your inquiry to [email protected] or by calling 855.891.9415. Our team is dedicated to supporting your efforts to provide the best possible care for your patients.

References

  1. CPIC® Guidelines. ClinPGx Clinical Pharmacogenomic Resource. https://www.clinpgx.org/cpic/guidelines [accessed March 2026]
  2. Table of Pharmacogenetic Associations – U.S. Food and Drug Administration. https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations
Chat